131206-74-1

Usage

General Description

The chemical (+/-)-2,2-dimethyl-4,4-ethylendioxy-1-cyclohexanol, also known as dihydroactinidiolide, is a cyclic alcohol compound with a molecular formula of C12H22O2. It is commonly used as a fragrance ingredient in perfumes and personal care products due to its pleasant, sweet, and fruity odor. Dihydroactinidiolide is also found in various natural sources such as fruits, vegetables, and herbs, and is responsible for contributing to the characteristic aroma of these plant materials. Studies have also suggested potential biological activities of dihydroactinidiolide, including anti-inflammatory and antimicrobial properties, making it of interest in pharmaceutical and cosmetic applications. However, further research is needed to fully understand its potential therapeutic benefits and safety profile.

Upstream product

• 134409-06-6 4,4-ethylenedioxy-2,2-dimethylcyclohexanone 

Downstream Products

• 358749-85-6 4-(benzyloxy)-3,3-dimethylcyclohexanone 
• 358749-84-5 8-(benzyloxy)-7,7-dimethyl-1,4-dioxaspiro[4.5]decane 
• 888325-30-2 (+/-)-5-((2-methoxyethoxy)methoxy)-2-hydroxy-4,4-dimethylcyclohex-1-enecarboxylic acid methyl ester 
• 888325-28-8 (+/-)-3,3-dimethyl-4-[(2-methoxyethoxy)methoxy]-1-cyclohexanone 
• 888325-29-9 (+/-)-4-hydroxy-3,3-dimethylcyclohexanone 

Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention is directed to pyrazole derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases

HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS

The present invention relates to compounds (1) which bind to the NR1 H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds (1) for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites

We describe herein the development of novel huperzine A-tacrine hybrids characterized by 3-methylbicyclo-[3.3.1]non-3-ene scaffolds. These compounds were specifically designed to establish tight interactions, through different binding modes, with the midg